An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
This phase 1b study will determine the safety and efficacy of combined treatment of Abraxane
and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.
Participants may be eligible to join this study if they are aged 18 years or above and have
been diagnosed with metastatic breast cancer or inoperable locally advanced breast cancer.
All participants will receive a combination of intravenous Abraxane and an oral dose of
phenelzine sulfate. Abraxane will be administered weekly for the first 3 weeks of a 4-week
cycle for 3 consecutive cycles. Phenelzine sulfate will be taken daily for the duration of
the 3 cycles. Five patient cohort groups will receive a progressively increasing dose of
phenelzine sulfate. Safety and efficacy will be assessed weekly over the 3 cycles of
treatment.
Although both drugs have been used in clinical care for more than a decade, they have not
been intentionally combined together in a cancer therapy setting. This means that the
combined effect of these two drugs has not been documented. This is being addressed in this
study.
Phase:
Phase 1
Details
Lead Sponsor:
EpiAxis Therapeutics
Collaborators:
Liverpool Cancer Therapy Centre Southern Medical Day Care Centre The Canberra Hospital